Study of Sedative Medications in Patients With Severe Infection and Respiratory Failure
| Status: | Recruiting |
|---|---|
| Conditions: | Hospital, Neurology, Pulmonary |
| Therapuetic Areas: | Neurology, Pulmonary / Respiratory Diseases, Other |
| Healthy: | No |
| Age Range: | 18 - 89 |
| Updated: | 1/10/2019 |
| Start Date: | August 2014 |
| End Date: | December 2019 |
| Contact: | Mark B Sigler, MD |
| Email: | mark.sigler@ttuhsc.edu |
| Phone: | 918-440-0475 |
PRO-DEFENSE: Propofol Versus Dexmedetomidine for Sedation in Mechanically Ventilated Patients With Sepsis
Patients with infections in their blood often become very sick. These patients are usually
put in an intensive care unit for careful observation and treatment. These patients may
develop a low blood pressure, lung failure, and kidney failure. When these problems develop,
care becomes quite complicated. Patients with lung failure often need help with a breathing
machine to make certain that the breathing is adequate. The machine helps keep the oxygen
level high enough for healthy tissues. When patients are placed on the machine for breathing
they require a tube to be placed into lungs. This can be quite uncomfortable. These patients
need sedation to help them tolerate the uncomfortable breathing tube and other parts of their
routine necessary care. This study will compare two drugs (dexmedetomidine and propofol)
which are frequently used for sedation in intensive care patients. Clinical studies suggest
that these drugs are both effective and safe. The main question is whether or not one of the
drugs is better in a patient with a blood infection. This study will try to determine that.
Our main goal is to see whether or not patients on one particular drug come off the breathing
machine faster than patients on the other drug. These drugs are not experimental drugs and
are approved by the Food and Drug Administration. There is no placebo drug being used in this
study. All patients in this study will receive the best possible care based on their medical
condition.
put in an intensive care unit for careful observation and treatment. These patients may
develop a low blood pressure, lung failure, and kidney failure. When these problems develop,
care becomes quite complicated. Patients with lung failure often need help with a breathing
machine to make certain that the breathing is adequate. The machine helps keep the oxygen
level high enough for healthy tissues. When patients are placed on the machine for breathing
they require a tube to be placed into lungs. This can be quite uncomfortable. These patients
need sedation to help them tolerate the uncomfortable breathing tube and other parts of their
routine necessary care. This study will compare two drugs (dexmedetomidine and propofol)
which are frequently used for sedation in intensive care patients. Clinical studies suggest
that these drugs are both effective and safe. The main question is whether or not one of the
drugs is better in a patient with a blood infection. This study will try to determine that.
Our main goal is to see whether or not patients on one particular drug come off the breathing
machine faster than patients on the other drug. These drugs are not experimental drugs and
are approved by the Food and Drug Administration. There is no placebo drug being used in this
study. All patients in this study will receive the best possible care based on their medical
condition.
Patients admitted to the MICU with acute respiratory care and possible sepsis will be
evaluated and managed by the internal medicine MICU team. This team includes faculty members,
pulmonary fellows, and internal medicine residents. These physicians will make all the
decisions regarding the initial management of the patient. The admitting team will be
approached by the study investigators to solicit their support for the recruitment of the
patient into the study. During some periods of time the study investigators will be directly
involved in the patient care.
The general approach to managing patients with sepsis includes blood cultures, serum lactate
levels, and empiric antibiotics. Other cultures from the respiratory tract, urinary tract,
and other sites are also obtained as indicated. Empiric antibiotic choices will be based on
the most likely source of infection. Patient will receive fluid administration and
vasopressors to maintain mean arterial pressure blood pressures greater than or equal to 60
mmHg.
Mechanical ventilation support will follow ARDS network guidelines. In general patients will
be on an assist-control mode, a low tidal volume (6 mm/kg ideal body weight), and a FiO2
adequate to maintain O2 saturations greater than equal to 90%. PEEP levels will be based on
the FiO2 using ARDS network recommendations. The ventilator management goal is to have the
lowest possible plateau pressure and lowest FiO2 possible to maintain adequate ventilation
and oxygenation.
Fentanyl will be routinely ordered for analgesia. Per current UMC policy, initial fentanyl
boluses will be given at 50mcg IV every 2 hours as needed to keep pain level less than 4/10.
At the discretion of the provider, a fentanyl drip may be administered if intermittent
fentanyl does not achieve adequate analgesia. If a fentanyl drip is initiated, the drip will
have a range of 25-200 mcg/hour to achieve a pain level of less than 4/10. If an allergy to
fentanyl is documented, the patient will be excluded from the study.
Once a mechanically ventilated patient with sepsis is selected for enrollment, the patient
will be randomized (via a computer-generated randomization program) to one of two sedation
arms: 1) propofol, or 2) dexmedetomidine.
Per current UMC policy, propofol will be initiated at 5 mcg/kg/minute (0.3mg/kg/hour) and
titrated every 5 minutes by 5mcg/kg/minute to RASS (Richmond Agitation and Sedation Scale)
goal -1 to +1. The maximum dose of propofol will be 80 mcg/kg/minute.
Dexmedetomidine will be initiated at 0.2 mcg/kg/hour and will be titrated every 5 minutes by
0.1mcg/kg/hour to a maximum dose of 1.4 mcg/kg/hour to a RASS goal of -1 to +1. Although
dexmedetomidine has only been approved in the United States for short-term sedation of ICU
patients (< 24 hrs) at a maximal dose of 0.7 μg/kg/hr (up to 1.0 μg/kg/h for procedural
sedation), several studies demonstrate the safety and efficacy of dexmedetomidine infusions
administered for greater than 24 hrs (up to 28 days) and at higher doses (up to 1.5
μg/kg/hr).
Daily sedation stops will be performed in both study arms per MICU weaning policy. Patients
will be allowed to return to a RASS of 0 to +1, and the physician will be alerted for
assessment. If the physician determines sedation needs to be re-started, it will be at 50% of
the dose prior to the sedation stop. This dose will then be titrated to a RASS goal of -1 to
+1.
Patients with inadequate sedation scores on their assigned drug will receive supplemental
sedation with midazolam or lorazepam using IV boluses as needed based on nursing and
physician assessment.
evaluated and managed by the internal medicine MICU team. This team includes faculty members,
pulmonary fellows, and internal medicine residents. These physicians will make all the
decisions regarding the initial management of the patient. The admitting team will be
approached by the study investigators to solicit their support for the recruitment of the
patient into the study. During some periods of time the study investigators will be directly
involved in the patient care.
The general approach to managing patients with sepsis includes blood cultures, serum lactate
levels, and empiric antibiotics. Other cultures from the respiratory tract, urinary tract,
and other sites are also obtained as indicated. Empiric antibiotic choices will be based on
the most likely source of infection. Patient will receive fluid administration and
vasopressors to maintain mean arterial pressure blood pressures greater than or equal to 60
mmHg.
Mechanical ventilation support will follow ARDS network guidelines. In general patients will
be on an assist-control mode, a low tidal volume (6 mm/kg ideal body weight), and a FiO2
adequate to maintain O2 saturations greater than equal to 90%. PEEP levels will be based on
the FiO2 using ARDS network recommendations. The ventilator management goal is to have the
lowest possible plateau pressure and lowest FiO2 possible to maintain adequate ventilation
and oxygenation.
Fentanyl will be routinely ordered for analgesia. Per current UMC policy, initial fentanyl
boluses will be given at 50mcg IV every 2 hours as needed to keep pain level less than 4/10.
At the discretion of the provider, a fentanyl drip may be administered if intermittent
fentanyl does not achieve adequate analgesia. If a fentanyl drip is initiated, the drip will
have a range of 25-200 mcg/hour to achieve a pain level of less than 4/10. If an allergy to
fentanyl is documented, the patient will be excluded from the study.
Once a mechanically ventilated patient with sepsis is selected for enrollment, the patient
will be randomized (via a computer-generated randomization program) to one of two sedation
arms: 1) propofol, or 2) dexmedetomidine.
Per current UMC policy, propofol will be initiated at 5 mcg/kg/minute (0.3mg/kg/hour) and
titrated every 5 minutes by 5mcg/kg/minute to RASS (Richmond Agitation and Sedation Scale)
goal -1 to +1. The maximum dose of propofol will be 80 mcg/kg/minute.
Dexmedetomidine will be initiated at 0.2 mcg/kg/hour and will be titrated every 5 minutes by
0.1mcg/kg/hour to a maximum dose of 1.4 mcg/kg/hour to a RASS goal of -1 to +1. Although
dexmedetomidine has only been approved in the United States for short-term sedation of ICU
patients (< 24 hrs) at a maximal dose of 0.7 μg/kg/hr (up to 1.0 μg/kg/h for procedural
sedation), several studies demonstrate the safety and efficacy of dexmedetomidine infusions
administered for greater than 24 hrs (up to 28 days) and at higher doses (up to 1.5
μg/kg/hr).
Daily sedation stops will be performed in both study arms per MICU weaning policy. Patients
will be allowed to return to a RASS of 0 to +1, and the physician will be alerted for
assessment. If the physician determines sedation needs to be re-started, it will be at 50% of
the dose prior to the sedation stop. This dose will then be titrated to a RASS goal of -1 to
+1.
Patients with inadequate sedation scores on their assigned drug will receive supplemental
sedation with midazolam or lorazepam using IV boluses as needed based on nursing and
physician assessment.
Inclusion Criteria:
- Men and women 18-89 years old
- with the diagnosis of sepsis (as specified below) within the previous 24 hours
- who require mechanical ventilation, and
- provide informed consent either personally or by an authorized representative.
Exclusion Criteria:
- Patients with documented allergies to propofol, dexmedetomidine, fentanyl, eggs or egg
products, or soy or soy products.
- A heart rate less than 50 beats/minute or grade 2 or 3 AV heart block
- Mean arterial pressure less than 55 mmHg despite appropriate fluid resuscitation and
vasopressor support.
- Current triglyceride level > 400 mg/dl
We found this trial at
1
site
Lubbock, Texas 79430
Principal Investigator: Kenneth Nugent, MD
Phone: 918-440-0475
Click here to add this to my saved trials
